News for Healthier Living
New Treatment Approach Improves Survival and Reduces Recurrence Risk for Patients With Muscle-Invasive Bladder Cancer
Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to an international phase 3 clinical trial published in The New England Journal of Medicine (DOI: 10.1056/NEJMoa2601486).
July 24, 2026
July 25 2026July 24 2026July 23 2026July 22 2026July 21 2026July 20 2026July 17 2026July 16 2026July 15 2026July 14 2026July 13 2026July 12 2026
|
|
|
|
|